Pneumococcal Vaccine Linked to Better COVID-19 Outcomes in IRD Patients: Study

Pneumococcal Vaccine Linked to Better COVID-19 Outcomes in IRD Patients: Study

Publication date: Jul 28, 2025

We have identified patients with one following of these IRD: rheumatoid arthritis (RA), spondyloarthritis (SpA) and psoriatic arthritis (PsA). We recorded 0. 9 % COVID-19 hospitalizations (n = 3574), 0. 24 % severe infections (n = 980), and 0. 17 % deaths (n = 697). Pneumococcal and influenza vaccination rate in this population were respectively 37. 8 % and 40. 5 %. (https://www. sciencedirect. com/science/article/pii/S0264410X25007364)

Concepts Keywords
Arthritis Covid
French Diseases
S0264410x25007364 Identified
Vaccinations Inflammatory
Influenza
Ir95
Ird
Outcomes
Patients
Pneumococcal
Rheumatic
Severe
Severity
Vaccination
Vaccine

Semantics

Type Source Name
drug DRUGBANK Coenzyme M
disease MESH COVID-19
disease MESH rheumatic diseases
disease IDO infection
disease IDO immune response
disease MESH death
disease MESH infections
disease MESH psoriatic arthritis
pathway KEGG Rheumatoid arthritis
disease MESH influenza
disease MESH rheumatoid arthritis
drug DRUGBANK Tropicamide

Original Article

(Visited 1 times, 1 visits today)